Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.
PlattRWilsonMChanKA, et al. The new Sentinel Network—improving the evidence of medical-product safety. N Engl J Med2009; 361(7): 645–647.
3.
PlattRBrownJSRobbM, et al. The FDA Sentinel Initiative—an evolving national resource. N Engl J Med2018; 379(22): 2091–2093.
4.
CocorosNMPokorneySDHaynesK, et al. FDA-Catalyst-Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: approach and lessons learned during the planning phase of the first trial. Clin Trials2019; 16(1): 90–97.
U.S. Food & Drug Administration. Guidance for industry and FDA staff: enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs, 2019, https://www.fda.gov/media/127712/download (accessed 13 September 2019).
7.
U.S. Food & Drug Administration. Guidance for industry and FDA staff: enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products, 2019, https://www.fda.gov/media/121320/download (accessed 13 September 2019).
8.
KimESBruinoogeSSRobertsS, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol2017; 35(33): 3737–3744.
9.
LinJGamalo-SiebersMTiwariR.Propensity-score-based priors for Bayesian augmented control design. Pharm Stat2019; 18(2): 223–238.
10.
U.S. Food & Drug Administration. Guidance for industry: E9 statistical principles for clinical trials, 1998, https://www.fda.gov/media/71336/download (accessed 13 September 2019).
11.
U.S. Food & Drug Administration. Guidance for industry: E10 choice of control group and related issues in clinical trials, 2001, https://www.fda.gov/media/71349/download (accessed 13 September 2019).
12.
HlatkyMARayRMBurwenDR, et al. Use of Medicare data to identify coronary heart disease outcomes in the Women’s Health Initiative. Circ Cardiovasc Qual Outcomes2014; 7(1): 157–162.
13.
BarrySJDinnettEKeanS, et al. Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study. PLoS ONE2013; 8(9): e75379.
14.
FordIMurrayHMcCowanC, et al. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation2016; 133(11): 1073–1080.
15.
CurtisMDGriffithSDTuckerM, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res2018; 53(6): 4460–4476.
16.
SchneeweissS.Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf2006; 15(5): 291–303.
17.
LashTLFoxMPMacLehoseRF, et al. Good practices for quantitative bias analysis. Int J Epidemiol2014; 43(6): 1969–1985.
18.
LashTLFoxMPCooneyD, et al. Quantitative bias analysis in regulatory settings. Am J Public Health2016; 106(7): 1227–1230.
19.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Draft guidance: E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials, 2017, https://www.fda.gov/media/108698/download (accessed 13 September 2019).
20.
HernanMARobinsJM.Per-protocol analyses of pragmatic trials. N Engl J Med2017; 377(14): 1391–1398.
21.
HernanMAScharfsteinD.Cautions as regulators move to end exclusive reliance on intention to treat. Ann Intern Med2018; 168(7): 515–516.
22.
LoudonKTreweekSSullivanF, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ2015; 350: h2147.
23.
FranklinJMPawarAMartinD, et al. Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project. Clin Pharmacol Ther. Epub ahead of print 21 September 2019. DOI: 10.1002/cpt.1633.
